-
Over 30 Class 1 new drugs were approved in clinical trials this week, including systemic lupus erythematosus, tumors and other fields
Time of Update: 2021-11-11
Johnson & Johnson's JNJ-63733657 injection clinical trial application was approved this week, and the indication is Alzheimer's disease .
The clinical trial application of GSK3511294 injection by GlaxoSmithKline was approved this week, and the indication is the adjuvant maintenance treatment for patients with severe eosinophilic asthma .
-
Jiang Zefei: Why do we formulate China's tumor clinical guidelines for NEJM promotion
Time of Update: 2021-11-04
The English version was published in the New England Journal of Medicine (NEJM) on October 21, 2021.
The PDF version and the interview video selection Available from NEJM CareerCenter official website (
-
Preview of the full version of the Chinese Anti-Cancer Association Guidelines and Specifications for the Diagnosis and Treatment of Breast Cancer (2021 Edition)
Time of Update: 2021-11-04
2021 version of CBCS guidelines and specifications full version 2021 version of CBCS guidelines and specifications refined version 2021 version of CBCS guidelines and specifications The small program "Pink Ribbon.
Health Guardian Milk What You Want" Yimaitong large-scale public welfare lectures sincerely invite you to participate .
-
【Nature Newsletter】Breakthrough!
Time of Update: 2021-11-04
Recently, a study published in "Nature Communications" shows that using the most advanced stem cell technology and next-generation DNA sequencing methods to compare diseased and healthy cells from the same patient, this The method can reveal the wrong new molecules in the development of GBM, and this significant molecular difference can determine new therapeutic targets .
-
Corning Jerry's HER2 dual-antibody KN026 Phase III clinical trial was officially accepted by CDE
Time of Update: 2021-11-04
On October 21, Corning Jereh Biopharmaceuticals and CSPC jointly announced that a phase III clinical trial application of recombinant humanized anti-HER2 bispecific antibody KN026 (study number: KN026-306) has been officially accepted by CDE and will start Combination chemotherapy is used in the registration clinical study of advanced gastric cancer/gastroesophageal junction adenocarcinoma with disease progression after first-line standard chemotherapy .
-
The pCR rate of the neoadjuvant PD-1 monoclonal antibody for the treatment of colorectal cancer by Professor Yanhong Deng’s team was as high as 88%, and was invited to be published by the Lancet Gastrointestinal and Liver Disease Sub-Journal
Time of Update: 2021-11-04
486) published online the latest research results in the field of colorectal cancer immunotherapy by Professor Deng Yanhong's team at the Sixth Affiliated Hospital of Sun Yat-sen University——" Neoadjuvant teriprimab (anti-PD-1 monoclonal antibody) with or without celecoxib (COX-2 inhibitor) for the treatment of mismatch repair protein defects (dMMR) or highly unstable microsatellites (MSI-H) ) Single-center, parallel, non-controlled, randomized, phase II clinical trial (PICC) for locally advanced colorectal cancer" .
-
PD-1 inhibitor combined with ADC opens up a new direction for the treatment of advanced and metastatic urothelial cancer 2021 CSCO famous doctor Kung Fu tea
Time of Update: 2021-11-04
In the past few decades, the traditional first-line treatment program is mainly cisplatin-based systemic therapy, including gemcitabine + cisplatin (GC) regimen, dose-enhanced methotrexate + adriamycin + vincristine + cisplatin Platinum (ddMVAC) programs have certain clinical benefits[1,2], and the objective response rate (ORR) is about 40%, but the 5-year overall survival rate of mUC is still <10%[3] .
-
Cancer Research Liu Wen/Yang Yunlong collaborated to report a new mechanism for hyperglycemia to promote tumor metastasis through megakaryocytes
Time of Update: 2021-11-04
The authors used a variety of metastasis models to verify the role of the glucose-megakaryocyte-MYC-GRP75-Ca2+-PKCα signaling axis in activating platelets and indirectly promoting tumor metastasis .
-
"Nature" published a new design strategy for PROTAC molecules, significantly improving protein degradation efficiency and anti-cancer activity
Time of Update: 2021-11-04
▲The trivalent PROTAC molecule more effectively induces apoptosis of cancer cell lines (picture source: Reference [1]) The researchers pointed out in the discussion section of the paper that the PROTAC molecule can form a stable ternary with the target protein and E3 ligase The ternary complex is the key to improving the efficiency of protein degradation .
-
Clinical Application of Nanobodies in Six Major Tumors
Time of Update: 2021-11-04
Because the nanobody has a small molecular weight and good tissue penetration, the imaging time is fast (1-3 hours), the clearance in the body is also fast, and the tumor/background ratio is higher.
-
Circulating tumor cells: help early detection and treatment of tumors
Time of Update: 2021-11-04
The Chinese Society of Clinical Oncology (CSCO) prostate cancer diagnosis and treatment guidelines also point out that CTC detection can detect tumor micrometastasis or residual disease in the body earlier than imaging, early prediction of prostate cancer patients with high risk of recurrence and metastasis, and regular follow-up monitoring of CTC, which can reflect patients in real time The level of tumor burden in the body helps doctors monitor the condition .
-
CSCO Annual Meeting Interview Listening to Professor Ye Dingwei and He Zhisong's Interpretation of Diagnosis, Treatment and Management of Prostate Cancer
Time of Update: 2021-11-04
Professor He Zhisong said that the year-on-year increase in the incidence of prostate cancer in China is mainly based on the increasingly serious problem of population aging, people's awareness of disease screening, and the country's strong support for public medical and health institutions .
-
The risk of SARS-CoV-2 reinfection in people who have recovered from COVID-19
Time of Update: 2021-11-04
Comment by Thomas Glück, MDSARS-CoV-2 high-risk groups of reinfection include adults, women, and immune People with low function and those who have been hospitalized with COVID-19 .
-
Nature's heavyweight: ketogenic diet cannot fight cancer, but calorie restriction diet can cut off lipid supply and inhibit tumor growth
Time of Update: 2021-11-04
And further revealed the underlying mechanism: calorie restriction not only reduces blood lipid levels in plasma and tumors, but also reduces stearoyl-CoA desaturase (SCD) activity, resulting in cancer cells not being able to obtain lipids from the diet, but also It is difficult to produce by oneself, which leads to the restriction of tumor growth .
-
Challenges and improvement strategies of TcE bispecific antibodies
Time of Update: 2021-11-04
The affinity and effectiveness of the CD3 binding arm are important to ensure that there is no target-independent T cell activation.
However, the current preclinical model research shows that the size of the bispecific TcE molecule does not seem to hinder its entry and formation of strong immune synapses.
-
How to choose melanoma treatment?
Time of Update: 2021-11-04
Although the track of CAR-T treatment of solid tumors has always been facing the need to improve the level of targeted molecules, because the levels of melanoma antigens from different sources are naturally different, there are still many companies looking for the treatment of specific entities.
-
The latest CSCO neuroendocrine tumor guide is mastered in one article
Time of Update: 2021-11-04
At the same time, due to the heterogeneity of NENs and individual differences in patients, there is much uncertainty between clinical diagnosis and treatment behavior and outcomes .
-
Can targeted/immunotherapy become the "key" to the survival of stage III non-small cell lung cancer?
Time of Update: 2021-11-04
■ Neoadjuvant treatment plan of atilizumab combined with chemotherapy This open-label, multi-center, single-arm, phase II study included patients ≥18 years of age, stage IB-IIIA resectable NSCLC, and ECOG score of 0-1 Patient .
-
Medicine Y is here!
Time of Update: 2021-11-04
This approval makes "Immune Gemini" the first new systemic therapy that brings survival benefits to patients with malignant pleural mesothelioma in 15 years, and the era of dual immunotherapy in China has officially opened!
-
Trends in Cancer Editor's Choice: Showing the Spirit of Trends
Time of Update: 2021-11-04
Reis from the University of Porto in Portugal published an opinion article, conceiving that glycan targeted therapy has the potential to open a new era of cancer treatment, and discussing the use of cancer-related glycosylation for the development of effective cancer drugs Prospects .
